{
    "clinical_study": {
        "@rank": "112626", 
        "arm_group": [
            {
                "arm_group_label": "Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "clopidogrel: 75mg once a day"
            }, 
            {
                "arm_group_label": "Ticagrelor", 
                "arm_group_type": "Experimental", 
                "description": "ticagrelor: 90mg twice a day"
            }
        ], 
        "brief_summary": {
            "textblock": "Objectives: To compare the effects of clopidogrel versus ticagrelor on atherosclerotic\n      plaque inflammation using serial FDG PET/CT imaging of carotid artery and ascending aorta.\n\n      Hypothesis: Thrombosis and inflammation are tightly linked rather than separate entities.\n      Therefore, P2Y12 receptor inhibitors may have an anti-ischemic effect by inhibiting plaque\n      inflammation, and ticagrelor may be superior in efficacy to clopidogrel."
        }, 
        "brief_title": "Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque, Atherosclerotic", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Plaque, Atherosclerotic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or Women at least 18 years of age inclusive\n\n          -  Patients with acute coronary syndromes (unstable angina pectoris Braunwald class IB,\n             IC, IIB, IIC, IIIB, IIIC, NSTEMI or STEMI)\n\n          -  FDG PET/CT shows at least 1 hot uptakes at carotid and or ascending aorta\n\n          -  The patient or guardian agrees to the study protocol and the schedule of clinical and\n             FDG PET/CT follow-up, and provides informed, written consent, as approved by the\n             appropriate Institutional Review Board/Ethical Committee of the respective clinical\n             site.\n\n        Exclusion Criteria:\n\n          -  Patients treated with carotid endarterectomy or stent placement\n\n          -  Chronic disease requiring treatment with oral, intravenous, or intra-articular\n             corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).\n\n          -  Untreated hyperthyroidism, or hypothyroidism\n\n          -  Any clinically significant abnormality identified at the screening visit, physical\n             examination, laboratory tests, or electrocardiogram which, in the judgment of the\n             Investigator, would preclude safe completion of the study.\n\n          -  Evidence of congestive heart failure, or left ventricular ejection fraction < 40%.\n\n          -  Significant renal disease manifested by serum creatinine > 2.0mg/dL, or creatinine\n             clearance of < 40 ml/min (by Cockcroft-Gault method).\n\n          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation\n             (ALT or AST > 3 times upper limit of normal).\n\n          -  History of adult asthma manifested by bronchospasm in the past 6 months, or currently\n             taking regular anti-asthmatic medication(s).\n\n          -  Unwillingness or inability to comply with the procedures described in this protocol.\n\n          -  Patient's pregnant or breast-feeding or child-bearing potential.\n\n          -  Type I Diabetes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905566", 
            "org_study_id": "AMCCV2012-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Clopidogrel", 
                "description": "75mg once a day", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ticagrelor", 
                "description": "90mg twice a day", 
                "intervention_name": "Ticagrelor", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticlopidine", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Plaque, Atherosclerotic", 
            "clopidogrel", 
            "ticagrelor", 
            "Fluorodeoxyglucose F18", 
            "Positron-Emission Tomography and Computed Tomography"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "location": {
            "contact": {
                "email": "cheolwlee@amc.seoul.kr", 
                "last_name": "Cheol-whan Lee, MD, PhD", 
                "phone": "82-2-3010-6158"
            }, 
            "contact_backup": {
                "email": "cvcrc10@amc.seoul.kr", 
                "last_name": "Jeong-youn Bae", 
                "phone": "82-2-3010-7259"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Cheol-whan Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation: Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta", 
        "overall_contact": {
            "email": "cheolwlee@amc.seoul.kr", 
            "last_name": "Cheol-whan Lee, MD, PhD", 
            "phone": "82-2-3010-3158"
        }, 
        "overall_contact_backup": {
            "email": "cvcrc10@amc.seoul.kr", 
            "last_name": "Jeong-youn Bae", 
            "phone": "82-2-3010-7259"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Cheol-whan Lee, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analyses of FDG activity will be quantified on common carotid arteries and ascending aorta of the aortic arch. Primary endpoint is change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest, known as a target-to-background ratio(blood-normalized standardized uptake value).", 
            "measure": "change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest", 
            "safety_issue": "No", 
            "time_frame": "6months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905566"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "CHEOL WHAN LEE, M.D., Ph.D", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serial changes of high-sensitivity C-reactive protein", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "lipid battery (total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol).", 
                "measure": "Serial changes of lipid battery", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "CHEOL WHAN LEE, M.D., Ph.D", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}